Signal MSK trial reports 90% survival among immune responders in pancreatic cancer

Summary

Against a global five-year pancreatic cancer survival rate of about 13 percent, the chapter reports a Memorial Sloan Kettering trial of custom vaccines built on tumour DNA changes and delivered by mRNA, in which survival among patients whose immune systems responded after their last treatment was 90 percent over the six-year study.